Alseres Pharmaceuticals to Host 2008 First Quarter Confe...( HOPKINTON Mass. May 9 /- AlseresP...),Health
Navigation Links
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
Date:5/9/2008
HOPKINTON, Mass., May 9 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a conference call on Thursday, May 15th, 2008 at 9:00am EDT to review the first quarter ending March 31, 2008 and discuss other matters related to the Company.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )
To access the conference call, please dial 877-795-3649 for domestic and 719-325-4817 international. The code for this conference call is 1073493. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the conference call and will be available through Thursday, May 29th, 2008.
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of
therapeutic and diagnostic products primarily for disorders in the central
nervous system (CNS). The Company maintains a world-class intellectual
property position in the field of regenerative therapeutics. The Company's
focus is reflected in several important initiatives. Cethrin, a
recombinant-protein-based drug designed to promote nerve repair after acute
spinal cord injury, demonstrated positive interim results in a Phase I/IIa
clinical trial. The Company's research and pre-clinical programs include,
Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for
the treatment of ocular injury and disease and research programs directed
at a number of regenerative therapies including bone repa
'/>"/>
| SOURCE Alseres Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
2. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
3. Alseres Pharmaceuticals, Inc. Raises $5 Million
4. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
5. Vion Pharmaceuticals to Appeal Nasdaq Delisting
6. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
7. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
8. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
9. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
Post Your Comments:
(Date:11/25/2009)...K,Nov.25/PRNewswire/--Reportlinker.comannouncestha...: ,, TheMarketforAnti-ageingFoods(2ndEdition)...-Market-for-Anti-ageing-Foods-(2nd-Edition ).html ...elopatafastpacewithgrowthoutstrippingthatofconvent...andHealthClaimsDirective,sstrictapproachtohealthcl...
(Date:11/25/2009)...IFFLAKE,N.J.,Nov.25/PRNewswire-FirstCall/--ParPhar...theresultsofits"ModifiedDutchAuction"tenderoffer,i...aggregateprincipalamount,oruptoapproximately82.7%,...eNotesdue2010. ,, BasedonthecountbyAmericanStoc...tenderoffer,$30,805,000aggregateprincipalamountoft...
(Date:11/25/2009)...mily members can panic, underestimate effects of ...lthDay News) -- Thanksgiving is a time of eating t...ng your elderly loved one to the emergency room. ,... why: When family members who have not seen each o...hey are often alarmed by the health of their older...
(Date:11/25/2009)... Beginning Today through Sunday, Novemb...very memory foam and latex sofa bed mattress + an ...ing and a 100 night money back guarantee. Use the ...t to take advantage of this special offer. , ...illions of Americans will travel from Thanksgiving...
(Date:11/25/2009)... The American Society of Hematology (AS...lishing, education, and media company, are launchi...ynamic science curriculum designed to spark intere...ion to exposing students to exciting career opport...Washington (PRWEB) November 25, 2009 -- The Americ...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 2Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 3Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 4Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 5Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 6Health News:Par Pharmaceutical Announces Results of Its 'Modified Dutch Auction' Tender Offer 2Health News:ER Visits for Elderly Rise During Thanksgiving 2Health News:ER Visits for Elderly Rise During Thanksgiving 3Health News:Providing Comfort for Holiday Guests Just Got Easier 2Health News:Providing Comfort for Holiday Guests Just Got Easier 3Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 2Health News:New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology 3[0] Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition)[0] Par Pharmaceutical Announces Results of Its 'Modified Dutch Auction' Tender Offer[0] ER Visits for Elderly Rise During Thanksgiving [0] Providing Comfort for Holiday Guests Just Got Easier[0] New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology
... Aug. 4 U.S. Preventive Medicine, the leader in,d...pleted its participation,in a major pilot project ...(NCQA) to evaluate The Prevention Plan(TM), its gr... the agreement, U.S. Preventive Medicine is one of...
...ORO, N.C., Aug. 4 Medical Justice Services,Inc., ...sts defend,themselves against meritless medical ma...roduced a new way for physicians and dentists to f...nd blogs, solves a problem that,s exploded in the,...
...SBURGH, Aug. 4 Antiretroviral drugs for HIV do no...a central risk factor for heart disease, according...aduate School of Public Health to be published in ... protection against atherosclerosis hardening of ...
... In the white paper, "All ...tes Senior Consultant Jay Gordon Cone provides a m...s leaders assess if their teams are high-performin...environments. Yet in many companies, http://www.i...
... A paper published in the Inter...the Fudan-Cinpathogen Clinical and Molecular Resea...aboration with the University of Colorado, and Cin...iagnosis and classification were performed by a si...
...vals consistent with current US treatment guidelin...mbination therapies, - Up to 80% of patients may ... blood pressure goals, - Singl...e approvals may benefit patients who are likely to...
Other Medicine News:Health News:National Committee for Quality Assurance Selects U.S. Preventive Medicine for Health Promotion Pilot Project 2Health News:Medical Justice Services Inc. Now Offers Online Anti-Defamation Service 2Health News:Medical Justice Services Inc. Now Offers Online Anti-Defamation Service 3Health News:Long-term HIV treatment may reduce risk for atherosclerosis 2Health News:New White Paper by Performance Improvement Innovator Interaction Associates Helps Business Leaders Assess Team Effectiveness 2Health News:Fudan-Cinpathogen Study Shows Chronic Lymphoid Neoplasms are More Common in Shanghai Than Thought 2Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 2Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 3Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 4Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 5Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 6Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 7National Committee for Quality Assurance Selects U.S. Preventive Medicine for Health Promotion Pilot ProjectMedical Justice Services Inc. Now Offers Online Anti-Defamation ServiceLong-term HIV treatment may reduce risk for atherosclerosisNew White Paper by Performance Improvement Innovator Interaction Associates Helps Business Leaders Assess Team EffectivenessFudan-Cinpathogen Study Shows Chronic Lymphoid Neoplasms are More Common in Shanghai Than ThoughtSingle-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure
(Date:11/24/2009)...Newswire/--Inadditiontofamily,friendsandhealth,can...toherThanksgivinggratitudelist. ,, "Theyheardth...esaidofMonday,sverdictstotaling$103millionindamage...g12,000womennationwidewhohavesuedWyethandPfizerpha...nandPrempro.Wisneskiandtheothervictimsofhormonethe...
(Date:11/24/2009)...RNewswire/--SpartaSystems,Inc.,themakerofTrackWise...mpliancesolutions,todayannouncedthatSSLInternation...eparentcompanyforgloballyrecognizedbrandssuchasDur...ityManagementSystem(EQMS).Thecompanyisnowleveragin...operationsthatincludeCorrectiveandPreventiveAction...
(Date:11/24/2009)...Newswire-Asia/--HuifengBio-Pharmaceutical,Technolo...dproducer,ofplantextractsandpharmaceuticalrawmater...oductioninXi,an,China,todayreportedthatinits,third..., RevenuesforthequarterendedSept.30,2009were$...23forthesamequarterin2008.Netincome,amountedto1,00...
Breaking Medicine Technology:Maryland Woman Thankful for Wyeth Verdicts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Improving schools for disabled students is NJIT researchers mission 59864 1Improving schools for disabled students is NJIT researchers mission 59864 2Improving schools for disabled students is NJIT researchers mission 59864 3Penn team uses self assembly to make molecule sized particles with patches of charge 10447 1Penn team uses self assembly to make molecule sized particles with patches of charge 10447 2Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 59862 1Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 59862 2Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 59862 3Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 59862 4Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 59862 5Experts Issue Call to Reconsider Screening for Breast Cancer and Prostate Cancer 59862 6...SCO, Dec. 8 Millennium: The Takeda Oncology Compa...d follow up of patients from the large, internatio...vival improvement for patients with previously unt...nd prednisone (VcMP). The VELCADE combination demo...oups, including those with poor prognostic charact...
...SCO, Dec. 8 Millennium: The Takeda Oncology,Compa...multi-center,randomized Phase III clinical trials ...eatment of transplant-eligible patients with previ...rogression-free survival (PFS) was observed,in one...ith vincristine,adriamycin and dexamethasone (VAD)...
Other Medicine Technology:Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 2Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 3Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 4Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 5Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 6Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 7Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple MyelomaProlonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |